Optimized peptides
for the next era
of human health.
Nexus Peptide Sciences is a biotechnology company developing high-purity peptide formulations and next-generation delivery systems engineered for convenience, absorption, stability, for real-world use across metabolic health.
Building the most advanced platform for optimized peptide therapeutics and delivery.
Peptides represent one of the fastest advancing frontiers in human health. They are highly precise, naturally occurring biological molecules, and our understanding of their potential continues to grow. Yet despite this progress, most peptide formulations remain limited by poor bioavailability, fragile chemistry, and delivery methods that have changed very little over the past several decades.
Nexus Peptide Sciences exists to optimize that gap. We engineer peptide molecules and the systems that deliver them, improving stability, absorption, and the practical experience of use across clinical-adjacent and consumer wellness markets.
Our work spans formulation chemistry, transdermal, oral, and other delivery systems. Our peptides are run through rigorous verification of testing.
The result is a platform designed to support the rapidly expanding peptide market with a responsible, science-driven approach. Built for research, professional, and consumer health applications, it is designed to evolve alongside a regulatory landscape that continues to mature.
Operators, scientists, and capital-markets veterans building the platform.
Terry Butler brings more than 30 years of entrepreneurial, operational, and strategic leadership experience across the life sciences, technology, and private business sectors.
Mr. Butler was a founder, officer, and director of StemSource, one of the pioneering companies in the stem cell industry. Under his leadership, StemSource grew into a recognized innovator before being successfully acquired by a NASDAQ-listed public company. He also served as an officer of Carnyx Therapeutics, an early-stage biotechnology company focused on peptide-based therapeutics.
Earlier in his career, Mr. Butler was the first Chief Financial Officer of eTapestry, where he helped build the company's financial infrastructure and played a key role in raising growth capital. eTapestry went on to become a leading provider of fundraising software for nonprofits and was subsequently acquired by Blackbaud, a global leader in software and services for the social impact sector.
Mr. Butler earned his MBA from Harvard Business School and spent four years on Wall Street, developing expertise in finance, capital markets, and corporate strategy. Over the past three decades, he has successfully acquired, operated, and exited numerous privately held businesses across a diverse range of industries, bringing extensive experience in company building, strategic growth, mergers and acquisitions, fundraising, and value creation.
At Nexus, Mr. Butler provides strategic leadership, business development expertise, and a proven track record of helping innovative companies grow from early-stage development through commercialization and successful exit.
Dr. Jamieson is a distinguished Professor of Chemical Biology, entrepreneurial scientist, and internationally recognised authority in peptide therapeutics, peptidomimetics and translational drug discovery. Renowned for his pioneering design of macrocyclic peptides, peptidomimetics and covalent therapeutics against highly challenging targets including GPCRs, ion channels and infectious-disease proteins, he combines deep mechanistic chemistry with strategic, outcome-focused translational science.
As founding Director and Chief Scientific Officer of Keltic Pharma Therapeutics, Dr. Jamieson architects a proprietary cyclic peptide and peptide-to-small-molecule discovery platform that fuses genetically encoded libraries, state-of-the-art macrocyclic chemistry, structural biology, cryo-EM, and AI/ML-guided molecular design with rigorous medicinal chemistry and direct-to-biology screening. Under his scientific leadership the company has secured and stewarded in excess of $10M in translational and venture-linked funding from premier partners including the Bill & Melinda Gates Foundation, the EU Malaria fund and Innovate UK, and has advanced first-in-class covalent anti-malarial programmes through hit-to-lead and lead optimisation.
At the University of Glasgow he leads the Chemical Biology and Organic Synthesis Research Section, directing interdisciplinary teams across medicinal chemistry, structural biology and pharmacology and serving as principal investigator on major collaborative programmes. A fellow of the Royal Society of Chemistry, Editorial Board member of Peptide Science and frequent international keynote speaker, Dr. Jamieson is a sought-after scientific advisor to industry and government, contributing to IP strategy, platform commercialisation and high impact translational partnerships.
Patrick T. Gunning is a Professor of Molecular Therapeutics at the University of Glasgow, Professor of Chemistry at the University of Toronto and previously a Canada Research Chair in Medicinal Chemistry, founder and inaugural Director of Centre for Medicinal Chemistry.
Dr. Gunning earned his Ph.D. from the University of Glasgow and completed postdoctoral studies at Yale University. He has authored over 140 research publications and received numerous accolades, including the Boehringer Ingelheim Young Investigator Award, the RSC MedChemComm Emerging Investigator Lectureship, and recognition as one of Canada's Top 40 Under 40. Patrick is a Fellow of the Royal Society for Chemistry.
Beyond academia, he has co-founded multiple biotech companies, including Janpix Inc., publicly traded Centessa Pharmaceuticals (CNTA) which was recently bought by Eli Lilly in H1 2026 for $7.8 Billion USD, Dunad Therapeutics, Dalriada Drug Discovery, HDAX Therapeutics, and Carnyx Therapeutics, collectively securing over $100 million in funding. In 2021, Dunad Therapeutics entered a strategic collaboration with Novartis, potentially worth up to $1.3 billion, to develop next-generation oral targeted protein degrader therapies.
Mr. Christopher Cherry has over 20 years of corporate accounting and audit experience. Mr. Cherry has extensive corporate experience and has held senior level positions for several public mining companies including Director, Chief Financial Officer, and Secretary. Mr. Cherry is a CPA having obtained the Chartered Accountant designation in February 2009 and the Certified General Accountant designation in 2004.
In his former experience as an auditor, he held positions with KPMG and Davidson and Co. LLP in Vancouver, where he gained experience as an auditor for junior public companies, and an IPO specialist. His most recent accomplishment in H1 2026, Christopher Cherry completed a sale of lithium assets to Posco Argentina S.A.U. for US$65 million.
Dr. Charlotte de Araujo (HBSc, PhD, University of Toronto) is a molecular biologist and biochemist with more than 17 years of experience spanning academia, program leadership, and scientific consulting. She has held professorial appointments at York University and Toronto Metropolitan University, and served as an Adjunct Professor in the Molecular Sciences Graduate Program at the Yeates School of Graduate Studies.
Recognized with the 2023 Faculty of Science Excellence in Teaching Award, Dr. de Araujo has extensive experience coordinating and leading large-scale biology and biochemistry programs across multiple Ontario universities. In addition to her academic leadership, she works as a consultant, supporting scientific and interdisciplinary initiatives.
Bailey is a communications and marketing professional with a B.S in Communications Media/Marketing from Indiana University of Pennsylvania. She combines exec-caliber office and operations management experience with a proven track record in business development, client stewardship, and digital marketing strategies — bringing a practical, results-oriented approach to growing brands and teams.
Since 2021, Bailey has served as a Project Manager at Sundar Capital Group, expanding her expertise to publicly listed companies on major Canadian and U.S Exchanges. At Sundar Capital Group she has become well versed in the roles of investor relations and public disclosure compliance and now serves as Head of Investor Relations for Carnyx Therapeutics, a peptide drug development company.
Bailey's competitive edge and leadership were shaped early on in her education as Valedictorian. She earned a scholarship to play on IUP's NCAA Woman's lacrosse team, where she developed discipline, teamwork, and resilience skills. This background led to a key role with Promino Nutritional Sciences, a sports nutrition company, where she serves as event coordinator and spokesperson, conducting media interviews at sporting events across North America.
Dr. Mark Lindsay is a Doctor of Chiropractic and Palmer Chiropractic College graduate with 35 years of experience working with elite athletes, including Super Bowl, Stanley Cup, and MLB Championship teams, Olympic and World Champions. A Diplomate with the American Chiropractic Neurology Board and member of both the Ontario and Colorado Chiropractic Associations, he is also a 2026 PhD Candidate in Neuroscience Program at Queen's University.
Dr. Lindsay has completed over 3,000 hours of graduate studies in Neurology through the Carrick Institute for Graduate Studies and trained for two decades under French osteopath Dr. Guy Voyer in the Fascia Fellowship Program. He is the author of Fascia: Clinical Applications for Health and Human Performance and 10 research publications and serves as a Research Fellow at the Steadman Philippon Research Institute in Vail, Colorado.
Founder of multiple practices and co-founder of biotech companies including Carnyx Therapeutics, Kelvin Therapeutics, and Entourage AI, Dr. Lindsay was named "Outstanding Field Doctor" by the Canadian Chiropractic Sports Fellowship in 1996 for his work with double Olympic Champion and World Record holder Donovan Bailey.
Patrick T. Gunning is a Professor of Molecular Therapeutics at the University of Glasgow, Professor of Chemistry at the University of Toronto and previously a Canada Research Chair in Medicinal Chemistry, founder and inaugural Director of Centre for Medicinal Chemistry.
Dr. Gunning earned his Ph.D. from the University of Glasgow and completed postdoctoral studies at Yale University. He has authored over 140 research publications and received numerous accolades, including the Boehringer Ingelheim Young Investigator Award, the RSC MedChemComm Emerging Investigator Lectureship, and recognition as one of Canada's Top 40 Under 40. Patrick is a Fellow of the Royal Society for Chemistry.
Beyond academia, he has co-founded multiple biotech companies, including Janpix Inc., publicly traded Centessa Pharmaceuticals (CNTA) which was recently bought by Eli Lilly in H1 2026 for $7.8 Billion USD, Dunad Therapeutics, Dalriada Drug Discovery, HDAX Therapeutics, and Carnyx Therapeutics, collectively securing over $100 million in funding. In 2021, Dunad Therapeutics entered a strategic collaboration with Novartis, potentially worth up to $1.3 billion, to develop next-generation oral targeted protein degrader therapies.
Mark Bell is a seasoned medicinal chemist with over two decades of experience spanning the biotech industry, contract research organizations (CROs), and academic drug discovery. He is the co-founder and Chief Technology Officer of Tay Therapeutics, where he has led the discovery and development of several innovative therapeutic candidates.
Mark spearheaded the discovery of Repibresib, a topical soft-drug pan-BET inhibitor currently in Phase 2a clinical trials for vitiligo, and VYN202, a BD2-selective oral BET inhibitor in Phase 1b trials for psoriasis. He also led the development of TAY-R1, an oral small molecule gene therapy targeting rare genetic diseases such as recessive dystrophic epidermolysis bullosa and Duchenne muscular dystrophy.
Mark is a co-founder of Hawkhill Therapeutics, focused on obesity and sarcopenia, and Entourage Diagnostics focused on proteomic biomarker analysis. During his time at the integrated drug discovery CRO Dalriada, he led the delivery of a preclinical candidate for postoperative pain for Antibe Therapeutics. While working with the Drug Discovery Unit at the University of Dundee he led on the discovery of a topical soft-drug SMO inhibitor preclinical candidate for Gorlin syndrome. At Almac Discovery, he contributed to the development of Phase 1b oncology candidates targeting Wee1 and Akt.
He has provided strategic consulting for KelticPharma Therapeutics on their PfCLK3 malaria program enabling successful proof-of-concept in the SCID mouse model and transition to LO. Mark is an inventor on 16 published patents across inflammation, rare diseases, and oncology therapeutic areas, reflecting his deep commitment to advancing translational science and improving patient outcomes.
Dr. Mark Lindsay is a Doctor of Chiropractic and Palmer Chiropractic College graduate with 35 years of experience working with elite athletes, including Super Bowl, Stanley Cup, and MLB Championship teams, Olympic and World Champions. A Diplomate with the American Chiropractic Neurology Board and member of both the Ontario and Colorado Chiropractic Associations, he is also a 2026 PhD Candidate in Neuroscience Program at Queen's University.
Dr. Lindsay has completed over 3,000 hours of graduate studies in Neurology through the Carrick Institute for Graduate Studies and trained for two decades under French osteopath Dr. Guy Voyer in the Fascia Fellowship Program. He is the author of Fascia: Clinical Applications for Health and Human Performance and 10 research publications and serves as a Research Fellow at the Steadman Philippon Research Institute in Vail, Colorado.
Founder of multiple practices and co-founder of biotech companies including Carnyx Therapeutics, Kelvin Therapeutics, and Entourage AI, Dr. Lindsay was named "Outstanding Field Doctor" by the Canadian Chiropractic Sports Fellowship in 1996 for his work with double Olympic Champion and World Record holder Donovan Bailey.
Dr. Elvin de Araujo is a scientist, entrepreneur, and drug discovery leader with extensive experience translating academic research into commercially viable therapeutics. He has led multiple drug discovery programs from early-stage research through preclinical development, helping bridge the gap between academia and industry.
Throughout his career, Dr. de Araujo has secured more than $14 million in research and philanthropic funding to support innovative drug discovery initiatives. He has managed a $1 million annual research budget, directing scientific strategy, experimental design, grant writing, team recruitment, and multidisciplinary research operations.
Dr. de Araujo has played a key role in technology transfer and intellectual property development, contributing to collaborations that supported the Novartis–Dunad Therapeutics $1.3 billion partnership (2021) and the Janpix–Centessa acquisition (2021). His experience spans scientific innovation, commercialization strategy, and the advancement of translational research into industry partnerships.
An accomplished fundraiser and scientific communicator, Dr. de Araujo has developed philanthropic cases for support and delivered presentations to foundations, donors, and strategic stakeholders. His contributions to biomedical research have been recognized with more than 20 research and academic awards.
Dr. de Araujo is also a Co-Founder of HDAX Therapeutics and Co-Founder of Gene2Lead, where he focuses on advancing next-generation therapeutic platforms and accelerating the translation of scientific discoveries into transformative medicines.
Danny Chan is a serial entrepreneur who has founded three venture-backed companies throughout his career and brings more than two decades of experience in private equity, finance, and media investment.
Mr. Chan began his finance career by investing in and helping life sciences companies access public capital markets through successful listings on major stock exchanges. He currently serves as Managing Director of Iconic Private Equity Partners, based in Hong Kong, where he has participated in the financing and public listing of more than 35 Asia-based companies.
In addition to his accomplishments in finance, Mr. Chan is an accomplished film producer, television producer, and financier with more than 25 film and television credits. He co-financed and produced, alongside New Regency, the 2022 blockbuster horror film Barbarian, which debuted as the #1 movie at the box office during its opening weekend. In 2026, Mr. Chan achieved another significant milestone when he sold his first television series to Netflix, further expanding his presence in the global entertainment industry.
Mr. Chan is the recipient of the Sagamore of the Wabash, the highest honor the Governor of Indiana can bestow upon a private citizen. The award recognizes individuals who have made significant contributions to the State of Indiana or rendered distinguished service to the Governor.
Throughout his career, Mr. Chan has been featured in numerous prominent media outlets, including The Wall Street Journal, Fox Business Network, Yahoo Finance, CBS News, Money Magazine, MarketWatch, Chicago Tribune, Chicago Sun-Times, Variety, and The Hollywood Reporter. Mr. Chan earned a Bachelor of Science in Finance from the Kelley School of Business at Indiana University.
Optimizing Core Peptides and Delivery Systems for the next era of human health.
Optimizing the molecule and the route, the gap that has gated real world peptide adoption for decades.
Peptides are short chains of amino acids that act as native signaling molecules, regulating metabolism, repair, immunity, and cognition. They are highly selective, structurally specific, and increasingly viewed as one of the most promising classes in modern therapeutics.
The historic limitation has not been the molecule itself but the route. Most peptides degrade rapidly, struggle to cross biological barriers, and require injection to remain stable. Nexus is built around closing that gap.
Indications
12+
Programs in active research
Purity
99.5%
Standard across formulations
Verification
3rd
Party batch testing
Molecular Optimization
Sequence and structural refinement to improve stability, half-life, and target selectivity without compromising native biological activity.
Sequence design Half-life
Formulation Chemistry
Excipient and carrier systems engineered for solubility, shelf-stability, and consistent dosing across temperature and handling conditions.
Stability Carriers
Delivery Systems
Needle-free formats including transdermal patches, oral platforms, and absorption-enhanced carriers designed for real-world adherence.
Transdermal Oral
Quality & Verification
Manufacturing in approved facilities with batch-level third-party analytical testing for identity, purity, and contamination.
GMP Third-party
Regulatory Alignment
Active monitoring of U.S. and international policy to align product positioning with the evolving framework for peptide-based therapies. We operate compliance-first and partner with manufacturing facilities held to pharmaceutical-grade standards.
Compliance first
Targeted peptide programs across the categories shaping the next decade of human health.
Materials, disclosure, and ongoing coverage for the financial community.
Corporate Disclosure
Official announcements, regulatory filings, and operational updates from Nexus Peptide Sciences.
PENDING
Nexus Peptide Sciences launches corporate platform
PENDING
Initial program portfolio announced
PENDING
Manufacturing partnership disclosure
Industry Coverage
Selected reporting on the peptide sector, policy developments, and the broader scientific landscape.
2026
Evolving U.S. policy on peptide-based therapies
2026
Growth of the metabolic and longevity peptide market
2025
Advances in transdermal delivery technology
Corporate Presentation
Current Nexus Peptide Sciences investor materials covering the platform, programs, market opportunity, team, and capital structure.
Corporate overview presentation
Fact sheet
Capital structure summary
Stay current on the Nexus platform.
Periodic updates on program progress, scientific developments, and corporate news. Sent directly. No noise.
SUBSCRIBE TO UPDATES
By subscribing you agree to receive periodic updates from Nexus Peptide Sciences. You can unsubscribe at any time.
Get in touch with the team at Nexus Peptide Sciences.
GENERAL
INVESTORS
MEDIA
MAILING